Keyphrases
Symptom Burden
100%
Patient-reported Symptoms
100%
Phase II Clinical Trial
100%
Rare Cancer
100%
Pembrolizumab
100%
Solid Tumors
28%
Diarrhea
28%
Rash
28%
MD Anderson Symptom Inventory (MDASI)
28%
Lack of Appetite
28%
Score-based
28%
Symptom Group
28%
Tumor
14%
Rare Malignancy
14%
Patient-completed
14%
Abdomen
14%
Early Phase Clinical Trials
14%
Prospective Longitudinal Study
14%
Specific Symptoms
14%
Drowsiness
14%
Trial Registration
14%
Sleep Disturbance
14%
Severe Symptoms
14%
Disturbed Sleep
14%
Specific Items
14%
Cancer Symptoms
14%
Composite Score
14%
Symptom Trajectories
14%
Group-based Trajectory Modeling
14%
Trial Experience
14%
Medicine and Dentistry
Cancer
100%
Clinical Trial
100%
Immunotherapy
100%
Pembrolizumab
100%
Solid Malignant Neoplasm
50%
Diarrhea
50%
Exanthem
50%
Neoplasm
25%
Fatigue (Symptom)
25%
Sleep Disorder
25%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Immunotherapy
100%
Pembrolizumab
100%
Solid Malignant Neoplasm
50%
Diarrhea
50%
Rash
50%
Neoplasm
25%
Sleep Disorder
25%
Nursing and Health Professions
Immunotherapy
100%
Pembrolizumab
100%
Solid Malignant Neoplasm
50%
Diarrhea
50%
Rash
50%
Neoplasm
25%
Longitudinal Analysis
25%
Sleep Disorder
25%
Neuroscience
Immunotherapy
100%
Lambrolizumab
100%
Longitudinal Study
25%
Sleep Disorder
25%
Psychology
Longitudinal Analysis
100%
Composite Score
100%